$230,000.00 in Sales Expected for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) This Quarter

Wall Street analysts predict that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will announce sales of $230,000.00 for the current quarter, according to Zacks. Five analysts have made estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from $130,000.00 to $290,000.00. Inovio Pharmaceuticals reported sales of $5.58 million during the same quarter last year, which would suggest a negative year over year growth rate of 95.9%. The firm is scheduled to announce its next quarterly earnings report on Monday, March 7th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year sales of $1.14 million for the current fiscal year, with estimates ranging from $1.00 million to $1.23 million. For the next year, analysts forecast that the company will report sales of $57.83 million, with estimates ranging from $700,000.00 to $268.33 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, November 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.19 million. Inovio Pharmaceuticals had a negative return on equity of 44.10% and a negative net margin of 3,391.88%. During the same period in the previous year, the business earned ($0.22) EPS.

A number of research firms recently weighed in on INO. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 5th. Royal Bank of Canada dropped their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Monday, November 1st. Finally, Bank of America downgraded Inovio Pharmaceuticals from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $9.00 to $8.00 in a research note on Friday, September 10th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.17.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in Inovio Pharmaceuticals by 1.1% during the third quarter. BlackRock Inc. now owns 18,369,653 shares of the biopharmaceutical company’s stock valued at $131,528,000 after purchasing an additional 197,952 shares during the period. State Street Corp boosted its holdings in shares of Inovio Pharmaceuticals by 7.9% in the second quarter. State Street Corp now owns 8,907,158 shares of the biopharmaceutical company’s stock worth $82,569,000 after acquiring an additional 651,621 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Inovio Pharmaceuticals by 9.1% in the second quarter. Geode Capital Management LLC now owns 3,623,488 shares of the biopharmaceutical company’s stock worth $33,589,000 after acquiring an additional 302,619 shares during the period. Wasatch Advisors Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 0.3% in the third quarter. Wasatch Advisors Inc. now owns 3,587,636 shares of the biopharmaceutical company’s stock worth $25,687,000 after acquiring an additional 10,930 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Inovio Pharmaceuticals by 117.6% in the second quarter. JPMorgan Chase & Co. now owns 3,437,056 shares of the biopharmaceutical company’s stock worth $31,862,000 after acquiring an additional 1,857,483 shares during the period. 34.45% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:INO traded up $0.02 during midday trading on Thursday, reaching $6.92. The company’s stock had a trading volume of 2,410,768 shares, compared to its average volume of 8,109,080. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -6.35 and a beta of 0.59. The company has a debt-to-equity ratio of 0.03, a quick ratio of 9.49 and a current ratio of 9.49. The firm has a 50 day moving average price of $7.16 and a two-hundred day moving average price of $7.90. Inovio Pharmaceuticals has a fifty-two week low of $5.81 and a fifty-two week high of $19.00.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B.

Featured Article: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.